| Literature DB >> 31637053 |
Anna Wójtowicz1, Małgorzata Zembala-Szczerba1, Dorota Babczyk1, Monika Kołodziejczyk-Pietruszka1, Olga Lewaczyńska2, Hubert Huras1.
Abstract
Recently, the diagnostic criteria of preeclampsia have been changed. No studies are available in the literature that analyzed in detail the differences between early-onset preeclampsia (EOP) and late-onset preeclampsia (LOP), taking into account the International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria. Thus, we sought to retrospectively investigate in detail the differences in clinical and laboratory outcomes between EOP and LOP diagnosed according to the ISSHP criteria. A retrospective cohort study was conducted in 214 women with singleton pregnancies and preeclampsia admitted to the Department of Obstetrics and Perinatology of the University Hospital in Kraków, Poland, from 2013 to 2017 (113 (52.8%) women with EOP and 101 (47.2%) women with LOP). Electronic medical records were reviewed for demographics and medical history, laboratory tests, and delivery and neonatal data. Patients with preeclampsia accounted for 1.7% of the women who delivered during the study period. The EOP and LOP groups did not differ in the distribution of risk factors for preeclampsia. The most common risk factor was primiparity, which was observed in 72.0% of cases. Regarding the ISSHP diagnostic criteria, the two groups differed in the incidence of fetal growth restriction (p=0.0009), hemolysis (p=0.0416), and neurological complications (p=00342), which were found more often in the EOP group. In addition, the EOP group had more frequent occurrence of severe cardiorespiratory (p < 0.0001) and hematological (p=0.0127) complications, adverse fetoplacental conditions (p < 0.0001), and severe fetoplacental complications (p=0.0003). Children born to women with EOP had lower Apgar scores (p < 0.001) and higher rates of intraventricular hemorrhage (p < 0.0001), respiratory disorders requiring mechanical ventilation (p < 0.0001), and early (p=0.0004) and late sepsis (p=0.002). EOP differed from LOP in terms of maternal and perinatal adverse outcomes. The observed higher rates of fetoplacental adverse conditions and severe complications indicate a significant contribution of impaired placentation to the etiopathogenesis of EOP.Entities:
Year: 2019 PMID: 31637053 PMCID: PMC6766116 DOI: 10.1155/2019/4108271
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Diagnostic criteria for preeclampsia [8].
| Blood pressure | Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg that are noted twice within 6 hours after 20 weeks of gestation in women with normal blood pressure before conception or in women with previous chronic hypertensive disorders |
|
| |
| And coexistence of one or more of the following new-onset conditions | |
| Proteinuria | Spot urine protein/creatinine >30 mg/mmol (0.3 mg/mg) or >300 mg/day or at least 1 g/L (“2+”) on dipstick testing |
|
| |
| Other maternal organ dysfunctions | (1) Renal insufficiency (creatinine >90 |
| (2) Liver involvement (doubling of serum transaminases and/or severe right upper quadrant pain) | |
| (3) Neurological complications (eclampsia, altered mental status, blindness, stroke, or more commonly hyperreflexia when accompanied by clonus and severe headaches when accompanied by hyperreflexia and persistent visual scotomata) | |
| (4) Hematological complications (platelet count <150,000/dL, DIC, and hemolysis) | |
|
| |
| Uteroplacental dysfunction | Fetal growth restriction |
DIC, disseminated intravascular coagulation.
The distribution of selected maternal risk factors for preeclampsia in women with singleton pregnancy and early- or late-onset preeclampsia.
| Risk factors for preeclampsia | EOP ( | LOP ( | Total ( |
|---|---|---|---|
| Primiparity, | 83 (73.4) | 71 (70.3) | 154 (72.0) |
| Multiparity (>3), | 3 (2.6) | 5 (5.0) | 8 (3.7) |
| Previous preeclamptic pregnancy, | 2 (1.7) | 2 (2.0) | 4 (1.8) |
| Chronic hypertension, | 20 (17.7) | 14 (14.0) | 34 (15.8) |
| Chronic renal disease, | 4 (3.5) | 2 (2.0) | 6 (2.8) |
| History of thrombophilia, | 2 (1.7) | 1 (1.0) | 3 (1.4) |
| In vitro fertilization, | 2 (1.7) | 3 (3.0) | 5 (2.3) |
| Family history of preeclampsia, | Data not available | Data not available | Data not available |
| Type 1 or type 2 diabetes mellitus, | 7 (6.2) | 8 (8.0) | 15 (7.0) |
| Obesity, BMI >30 kg/m2, | 13 (11.5) | 12 (12.0) | 25 (11.7) |
| Systemic lupus erythematosus, | 1 (0.9) | 0 (0.0) | 1 (0.4) |
| Maternal age ≥40 years, | 9 (8.0) | 4 (4.0) | 13 (6.0) |
BMI, body mass index; EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
The revised ISSHP criteria of preeclampsia [8, 9] in women with singleton pregnancy and early- or late-onset preeclampsia.
| Criterion | EOP ( | LOP ( | Total ( |
|
|---|---|---|---|---|
| Proteinuria | 113 (100.0) | 101 (100.0) | 214 (100.0) | ns |
| Renal insufficiency (creatinine >90 | 11 (9.7) | 6 (6.0) | 17 (7.9) | ns |
| Liver involvement, | 15 (13.3) | 8 (7.9) | 23 (10.7) | ns |
| Neurological complications, | 20 (17.7) | 8 (8.0) | 28 (13.0) | 0.0342 |
| Hematological complications, | 50 (44.2) | 35 (34.6) | 85 (39.7) | ns |
| (i) Thrombocytopenia, | 37 (74) | 29 (82.8) | 66 (77.6) | ns |
| (ii) DIC, | 0 (0.0) | 2 (5.8) | 2 (2.4) | ns |
| (iii) Hemolysis, | 13 (26) | 4 (11.4) | 17 (20.0) | 0.0416 |
| FGR, | 80 (70.7) | 49 (48.5) | 129 (60.3) | 0.0009 |
DIC, disseminated intravascular coagulation; EOP, early-onset preeclampsia; FGR, fetal growth restriction; ISSHP, International Society for the Study of Hypertension in Pregnancy; LOP, late-onset preeclampsia; ns, nonstatistically significant.
Characteristics and occurrence of adverse maternal outcomes in women with early-onset and late-onset preeclampsia.
| EOP ( | LOP ( | Total ( |
| |
|---|---|---|---|---|
| Maternal age at EDD, years ± SD (range) | 30.7 ± 5.5 (19.00–48.00) | 30.1 ± 5.3 (19.00–47.00) | 30.43 ± 5.4 (19.00–48.00) | ns |
| Gestational age at inclusion, weeks ± SD (range) | 30.0 ± 2.5 (22.0–33.0) | 36.2 ± 1.4 (34.0–39.3) | 33.1 ± 1.6 (22.0–39.3) | 0.00001 |
| Systolic blood pressure on admission, mmHg ± SD (range) | 178 ± 18 (140–240) | 168 ± 18 (120–230) | 173 ± 18 (120–240) | 0.005 |
| Diastolic blood pressure on admission, mmHg ± SD (range) | 109 ± 12 (90–150) | 104 ± 11 (70–145) | 106 ± 11 (70–150) | 0.026 |
| Antihypertensive drug administration, | ||||
| Methyldopa | 106 (93.8) | 90 (90.0) | 196 (94.8) | ns |
| Calcium channel blocker | 46 (40.7) | 29 (29.0) | 75 (35.0) | ns |
| Beta-blocker | 65 (57.5) | 26 (26.0) | 91 (42.5) | <0.001 |
| Resistant hypertension, | 34 (30.0) | 2 (2.0) | 36 (16.8) | <0.0001 |
| MgSO4 administered, | 65 (57.5) | 30 (30.0) | 85 (45.8) | <0.001 |
| Admission-to-delivery interval, days ± SD (range) | 6.8 ± 6.8 (1–30) | 6 ± 8.5 (1–53) | 6 ± 7.0 (1–53) | 0.021 |
| Gestational age at delivery, weeks ± SD (range) | 30.6 ± 2.2 (23.0–33.8) | 36.6 ± 1.4 (34.0–39.5) | 33.9 ± 1.9 (23.0–39.5) | <0.0001 |
| Delivery-to-discharge interval, days ± SD (range) | 6.7 ± 3.5 (3–24) | 6.4 ± 3.6 (3–30) | 6.5 ± 3 (3–30) | ns |
| Severe preeclampsia, | 109 (96.4) | 87 (87.0) | 196 (91.5) | 0.0412 |
| HELLP, | 5 (4.4) | 4 (4.0) | 9 (4.2) | ns |
| Eclampsia before delivery, | 0 (0.0) | 2 (2.0) | 2 (0.9) | ns |
| Postpartum eclampsia, | 17 (15.0) | 7 (7.0) | 24 (11.2) | ns |
| Placental abruption, | 19 (16.8) | 4 (4.0) | 23 (10.7) | 0.004 |
| Hemorrhage, | 3 (2.6%) | 1 (1.0) | 4 (1.8) | ns |
| Blood transfusion, | 12 (10.6) | 7 (7.0) | 19 (8.8) | ns |
| Albumin transfusion, | 22 (19.4) | 8 (8.0) | 30 (14.0) | 0.019 |
| Anemia, | 50 (44.2) | 40 (40.0) | 90 (42.0) | ns |
| Pulmonary edema, | 5 (4.4) | 0 (0.0) | 5 (2.3) | ns |
| Hysterectomy, | 0 (0.0) | 1 (1.0) | 1 (0.4) | ns |
| Maternal death, | 1 (0.8) | 0 | 1 (0.4) | ns |
| DIC, | 0 (0.0) | 2 (2.0) | 2 (0.9) | ns |
| ICU, | 22 (19.4) | 6 (6.0) | 28 (13.0) | 0.02 |
| Uterine contraction disorders, | 3 (2.6) | 1 (1.0) | 4 (1.8) | ns |
| Thrombosis, | 2 (1.7) | 4 (4.0) | 6 (2.8) | ns |
| Healing disorders of the scar, | 3 (2.6) | 6 (6.0) | 9 (4.2) | ns |
| Genitourinary infection, | 31 (27.4) | 15 (15.0) | 46 (21.5) | 0.0385 |
DIC, disseminated intravascular coagulation; EDD, estimated date of delivery; EOP, early-onset preeclampsia; HELLP, hemolysis, elevated liver enzymes, low platelets; ICU, intensive care unit; LOP, late-onset preeclampsia; ns, nonstatistically significant; SD, standard deviation.
Adverse conditions and severe complications in women with early-onset and late-onset preeclampsia.
| Organ system affected | EOP ( | LOP ( |
| |||
|---|---|---|---|---|---|---|
| Adverse conditions | Severe complications | Adverse conditions | Severe complications | Adverse conditions | Severe complications | |
| CNS, | 3 (2.6) | 17 (15.0) | 1 (1.0) | 7 (7.0) | ns | ns |
| Cardiorespiratory, | 2 (1.7) | 34 (30.0) | 1 (1.0) | 2 (2.0) | ns | <0.0001 |
| Hematological, | 37 (32.7) | 24 (21.2) | 29 (29.0) | 9 (9.0) | ns | 0.0127 |
| Renal, | 15 (13.2) | 2 (1.7) | 8 (8.0) | 1 (1.0) | ns | ns |
| Hepatic, | 15 (13.2) | 0 (0.0) | 8 (8.0) | 0 (0.0) | ns | ns |
| Fetoplacental, | 87 (77.0) | 21 (18.5) | 42 (42.0) | 3 (3.0) | <0.0001 | 0.0003 |
CNS, central nervous system; EOP, early-onset preeclampsia; LOP, late-onset preeclampsia; ns, nonstatistically significant.
Figure 1Proteinuria in women with early- and late-onset preeclampsia. EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
Laboratory measurements in women with early-onset and late-onset preeclampsia.
| EOP ( | LOP ( |
| |
|---|---|---|---|
| Proteinuria (g/L) | ( | ( | 0.007 |
| Proteinuria, | (91) | (78) | |
| ≤5 g/day, | 53 (58.2) | 59 (75.6) | ns |
| 5.1–9.9 g/day, | 16 (17.6) | 10 (12.8) | ns |
| ≥10 g/day, | 22 (24.2) | 9 (11.6) | 0.0122 |
| 24-hour urine proteinuria (g/24 h) | ( | ( | 0.008 |
| Blood urea nitrogen (mmol/L) | ( | ( | 0.021 |
| Uric acid ( | ( | ( | ns |
| Creatinine ( | ( | ( | 0.001 |
| Creatinine clearance (ml/min) | ( | ( | ns |
| Total serum protein (g/L) | ( | ( | ns |
| Albumin (g/L) | ( | ( | ns |
| Hemoglobin (g/L) | ( | ( | ns |
| Hematocrit (%) | ( | ( | ns |
| Erythrocytes (×109/L) | ( | ( | ns |
| Platelet (×109/L) | ( | ( | ns |
| Alanine aminotransaminase (U/L) | ( | ( | ns |
| Aspartate aminotransferase (U/L) | ( | ( | ns |
The values in ( ) indicate number of performed measurements; EOP, early-onset preeclampsia; LOP, late-onset preeclampsia; ns, nonstatistically significant; SD, standard deviation.
Figure 2Blood urea nitrogen of women with early- and late-onset preeclampsia. EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
Figure 3Creatinine of women with early- and late-onset preeclampsia. EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
Fetal factors associated with early- and late-onset preeclampsia.
| EOP ( | LOP ( | Total ( |
| |
|---|---|---|---|---|
| Gestational age at delivery, weeks ± SD (range) | 30.6 ± 2.2 (23.0–33.8) | 36.6 ± 1.4 (34.0–39.5) | 33.9 ± 1.9 (23.0–39.5) | <0.0001 |
| Birth weight (g), mean ± SD (range) | 1358 ± 497 (460–3450) | 2511 ± 689 (1010–4320) | 1934 ± 592 (460–4320) | <0.001 |
| Fetal sex | ||||
| Female, | 63 (56.0) | 53 (52.0) | 116 (54.0) | ns |
| Male, | 50 (44.0) | 48 (48.0) | 98 (46.0) | ns |
| Intrauterine fetal distress, | 78 (69.0) | 33 (33.0) | 111 (51.8) | <0.001 |
| UA PI >95th percentile, | 27 (23.9) | 15 (15.0) | 42 (19.6) | ns |
| MCA PI <5th percentile, | 52 (46.0) | 11 (11.0) | 63 (29.4) | <0.001 |
| CPR <5th percentile, | 79 (70.0) | 32 (32.0) | 111 (51.8) | 0.001 |
| FGR <10th percentile, | 80 (70.7) | 49 (49.0) | 129 (60.2) | 0.0015 |
| FGR <5th percentile, | 71 (62.8) | 46 (46.0) | 117 (54.6) | 0.006 |
| FGR <3rd percentile, | 66 (58.4) | 37 (37.0) | 103 (48.1) | 0.002 |
| Apgar score at 1 min, mean ± SD (range) | 6.7 ± 1.9 (1–10) | 9.1 ± 1.4 (1–10) | 7.9 ± 1.5 (1–10) | <0.001 |
| Apgar score at 3 min, mean ± SD (range) | 7.4 ± 1.7 (1–10) | 9.6 ± 0.7 (7–10) | 8.5 ± 1.4 (1–10) | <0.001 |
| Apgar score at 5 min, mean ± SD (range) | 7.8 ± 1.3 (4–10) | 9.8 ± 0.6 (7–10) | 8.8 ± 1.3 (4–10) | <0.001 |
| Apgar score <7 at 1 min, | 51 (45.0) | 4 (4.0) | 55 (25.7) | <0.001 |
| Apgar score <7 at 3 min, | 27 (23.9) | 2 (2.0) | 29 (13.5) | <0.001 |
| Apgar score <7 at 5 min, | 19 (16.8) | 0 (0.0) | 19 (8.8) | <0.001 |
| Intrauterine fetal death, | 1 (0.9) | 0 (0.0) | 1 (0.4) | ns |
| IVH, | 31 (27.4) | 1 (1.0) | 32 (14.9) | <0.0001 |
| FFP transfusion, | 15 (13.3) | 0 (0.0) | 15 (7.0) | 0.0002 |
| Mechanical ventilation | 33 (29.2) | 1 (1.0) | 34 (15.9) | <0.0001 |
| Infection complications, | ||||
| Early sepsis | 18 (16.0) | 1 (1.0) | 19 (8.8) | 0.0004 |
| Late sepsis | 20 (17.7) | 2 (2.0) | 22 (10.2) | 0.0021 |
| Retinopathy, | 2 (1.8) | 0 (0.0) | 2 (0.9) | ns |
| NEC, | 3 (2.6) | 0 (0.0) | 3 (1.4) | ns |
| Fetal death, | 13 (11.5) | 0 (0.0) | 13 (6.0) | 0.0008 |
| Born ≤28 weeks | 10 (8.8) | 0 (0.0) | 0.0058 | |
| Born >28 weeks | 3 (2.6) | 0 (0.0) | ns |
CPR, cerebroplacental ratio; FFP, fresh frozen plasma; FGR, fetal growth restriction; IVH, intraventricular hemorrhage; MCA, middle cerebral artery; NEC, necrotizing enterocolitis; ns, nonstatistically significant; PI, pulsatility index; RDS, respiratory distress syndrome; SD, standard deviation; UA, umbilical artery; EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
Figure 4Distribution of fetal growth in women with early- and late-onset preeclampsia. AGA, appropriate for gestational age; EOP, early-onset preeclampsia; FGR, fetal growth restriction; LOP, late-onset preeclampsia.